2017
OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143
Omuro A, Vlahovic G, Baehring J, Butowski N, Reardon D, Cloughesy T, Sahebjam S, Lim M, Zwirtes R, Sampson J. OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143. Neuro-Oncology 2017, 19: iii13-iii13. PMCID: PMC5463686, DOI: 10.1093/neuonc/nox036.044.Peer-Reviewed Original ResearchTreatment-related AEsAdverse eventsCheckMate 143Standard radiotherapyDisease progressionFirst prospective clinical trialHerpes simplex virus encephalitisTreatment-related adverse eventsTolerability of nivolumabTreatment-related deathsImmune checkpoint inhibitorsSimplex virus encephalitisDeath-1 receptorNew safety signalsPhase 2/3 studyProspective clinical trialsImmune cell infiltrationNovel therapeutic optionsMonoclonal antibody inhibitorMultiple cancer typesConcurrent temozolomideUnmethylated MGMTAdjuvant temozolomideCheckpoint inhibitorsRadiographic progression
2015
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015, 125: 1403-1410. PMID: 25568347, PMCID: PMC4342354, DOI: 10.1182/blood-2014-10-604561.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBusulfanCentral Nervous System NeoplasmsCombined Modality TherapyCyclophosphamideCytarabineFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansLymphoma, Non-HodgkinMaleMethotrexateMiddle AgedNeoplasm GradingNeoplasm StagingProcarbazinePrognosisRituximabSurvival RateThiotepaTransplantation, AutologousVincristineYoung AdultConceptsAutologous stem cell transplantProgression-free survivalHigh-dose chemotherapyPrimary central nervous system lymphomaStem cell transplantOverall survivalR-MPVHigh-dose methotrexate-based chemotherapyTwo-year progression-free survivalConsolidation high-dose chemotherapyMedian progression-free survivalCentral nervous system lymphomaMedian Karnofsky performance status 80Treatment-related deathsTwo-year OSCycles of chemotherapyMethotrexate-based chemotherapyObjective response ratePrimary end pointAcceptable toxicity profileMainstay of treatmentPhase 2 studyPrimary CNS lymphomaNervous system lymphomaBlood-brain barrier
2008
Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V. Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Journal Of Clinical Oncology 2008, 26: 2512-2518. PMID: 18413641, DOI: 10.1200/jco.2007.13.5533.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsBusulfanCombined Modality TherapyCyclophosphamideCytarabineEtoposideEye NeoplasmsFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesSalvage TherapySurvival RateThiotepaConceptsPrimary CNS lymphomaHematopoietic stem cell rescueStem cell rescueIntensive chemotherapyIntraocular lymphomaAutologous hematopoietic stem cell rescueMedian progression-free survival timeRecurrent primary CNS lymphomaProgression-free survival timeHigh-dose cytarabineMedian overall survivalTreatment-related deathsImmunocompetent adult patientsProspective multicenter trialFirst-line treatmentOverall survival probabilityPFS probabilityCNS lymphomaComplete remissionSalvage treatmentAdult patientsOverall survivalPartial responseRefractory diseaseMulticenter trial